Skip to main content

CSL Behring (Australia) Pty Ltd

Regulatory activities for this sponsor.

Sponsor content

3 result(s) found, displaying 1 to 3
  • Hemgenix (etranacogene dezaparvovec), a gene therapy, has been approved for the treatment of haemophilia B (congenital factor IX deficiency) in adults.
  • Hemgenix (etranacogene dezaparvovec) has been approved for the treatment of adults with haemophilia B (congenital factor IX deficiency).

Help us improve the Therapeutic Goods Administration site